留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性

刘国栋 周丽 张文静 王卓

刘国栋, 周丽, 张文静, 王卓. 粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性[J]. 药学实践与服务, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
引用本文: 刘国栋, 周丽, 张文静, 王卓. 粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性[J]. 药学实践与服务, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
LIU Guodong, ZHOU Li, ZHANG Wenjing, WANG Zhuo. Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
Citation: LIU Guodong, ZHOU Li, ZHANG Wenjing, WANG Zhuo. Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019

粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性

doi: 10.3969/j.issn.1006-0111.2018.02.019

Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis

  • 摘要: 目的 观察粒细胞巨噬细胞刺激因子(GM-CSF)联合全肺灌洗治疗特发性肺泡蛋白沉积症(IPAP)的疗效和安全性。 方法 选取2015年8月至2017年3月在第二军医大学附属长海医院就诊的2例IPAP患者,经全肺灌洗后,分别予皮下注射和雾化吸入GM-CSF治疗,观察其疗效和安全性。 结果 2例患者经GM-CSF联合全肺灌洗治疗,病情缓解。 结论 GM-CSF联合全肺灌洗治疗对IPAP患者治疗有效、用药安全。
  • [1] Huaringa AJ, Francis WH. Pulmonary alveolar proteinosis:a case report and world literature review[J]. Respirol Case Rep, 2016, 4(6):e00201.
    [2] 郭文亮, 曾运祥, 苏柱泉等. 粒细胞-巨噬细胞集落刺激因子雾化吸入治疗自身免疫性肺泡蛋白沉积症一例并文献复习[J]. 中华结核和呼吸杂志, 2015, 38(10):751-755.
    [3] Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis[J]. Science, 1994, 264(5159):713-716.
    [4] Stanley E, Lieschke G J, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology[J]. Proc Natl Acad Sci U S A, 1994, 91(12):5592-5596.
    [5] Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal[J]. Immunity, 1995, 2(3):211-222.
    [6] Griese M. Pulmonary alveolar proteinosis:a comprehensive clinical perspective[J]. Pediatrics,2017,140(2):e20170610.
    [7] 卢惠伦, 罗益锋. 体外膜肺氧合下行全肺大容量灌洗治疗肺泡蛋白沉积症1例并文献复习[J]. 现代医院, 2010, 10(3):13-14.
    [8] Xu Z, Jing J, Wang H, et al. Pulmonary alveolar proteinosis in China:a systematic review of 241 cases[J]. Respirology, 2009, 14(5):761-766.
    [9] 赵玉月, 徐作军. 肺泡蛋白沉积症的治疗进展[J]. 中华结核和呼吸杂志, 2014, 37(6):444-447.
    [10] Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis:new insights from a single-center cohort of 70 patients[J]. Respir Med, 2011, 105(12):1908-1916.
    [11] Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis[J]. Am J Respir Crit Care Med, 2001, 163(2):524-531.
    [12] Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis[J]. Chest, 2006, 130(1):227-237.
    [13] Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF[J]. Thorax, 2002, 57(3):277-280.
    [14] Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor:a low toxicity, lung-specific biological therapy in patients with lung metastases[J]. Clin Cancer Res, 1999, 5(9):2316-2323.
    [15] Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis[J]. Am J Respir Crit Care Med, 2010, 181(12):1345-1354.
  • 加载中
计量
  • 文章访问数:  3003
  • HTML全文浏览量:  309
  • PDF下载量:  863
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-05-29
  • 修回日期:  2017-12-07

粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性

doi: 10.3969/j.issn.1006-0111.2018.02.019

摘要: 目的 观察粒细胞巨噬细胞刺激因子(GM-CSF)联合全肺灌洗治疗特发性肺泡蛋白沉积症(IPAP)的疗效和安全性。 方法 选取2015年8月至2017年3月在第二军医大学附属长海医院就诊的2例IPAP患者,经全肺灌洗后,分别予皮下注射和雾化吸入GM-CSF治疗,观察其疗效和安全性。 结果 2例患者经GM-CSF联合全肺灌洗治疗,病情缓解。 结论 GM-CSF联合全肺灌洗治疗对IPAP患者治疗有效、用药安全。

English Abstract

刘国栋, 周丽, 张文静, 王卓. 粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性[J]. 药学实践与服务, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
引用本文: 刘国栋, 周丽, 张文静, 王卓. 粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性[J]. 药学实践与服务, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
LIU Guodong, ZHOU Li, ZHANG Wenjing, WANG Zhuo. Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
Citation: LIU Guodong, ZHOU Li, ZHANG Wenjing, WANG Zhuo. Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
参考文献 (15)

目录

    /

    返回文章
    返回